共 39 条
- [32] CHANGES IN INSULIN-LIKE GROWTH FACTOR-I AND GROWTH-HORMONE AND PREVENTION OF BONE LOSS DURING ESTROGEN REPLACEMENT THERAPY GROWTH REGULATION, 1992, 2 (03): : 101 - 107
- [33] Association Between Vitamin D and Carboxy-Terminal Cross-Linked Telopeptide of Type I Collagen in Children During Growth Hormone Replacement Therapy CLINICAL INVESTIGATION, 2018, 1047 : 53 - 60
- [35] Bone mineral density changes during an 18 month observational period following discontinuation of recombinant human parathyroid hormone (1-34) treatment of postmenopausal women receiving hormone replacement therapy. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S257 - S257
- [37] Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline Journal of Bone and Mineral Metabolism, 2004, 22 : 127 - 131
- [39] Time for a new, more inclusive endpoint for treatment of type 1 hepatorenal syndrome (HRS-1)? Small changes in serum creatinine (SCr) of >20% are equivalent to HRS reversal (HRSR) in predicting survival and need for renal replacement therapy (RRT) during treatment of HRS-1 with terlipressin and albumin. HEPATOLOGY, 2016, 64 : 1030A - 1031A